» Articles » PMID: 22348613

Preclinical Molecular Imaging of the Translocator Protein (TSPO) in a Metastases Model Based on Breast Cancer Xenografts Propagated in the Murine Brain

Overview
Journal Curr Mol Med
Specialty Molecular Biology
Date 2012 Feb 22
PMID 22348613
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have demonstrated the feasibility of translocator protein (TSPO) imaging to visualize and quantify human breast adenocarcinoma (MDA-MB-231) cells in vivo using a TSPO-targeted near-infrared (NIR) probe (NIR-conPK11195). This study aimed to extend the use of the TSPO-targeted probe to a more biologically relevant and clinically important tumor microenvironment as well as to assess our ability to longitudinally detect the presence and progression of breast cancer cells in the brain. The in vivo biodistribution and accumulation of NIR-conPK11195 and free (unconjugated) NIR dye were quantitatively evaluated in intracranial MDA-MB-231-bearing mice and non-tumor-bearing control mice longitudinally once a week from two to five weeks post-inoculation. The in vivo time-activity curves illustrate distinct clearance profiles for NIR-conPK11195 and free NIR dye, resulting in preferential accumulation of the TSPO-targeted probe in the intracranial tumor bearing hemisphere (TBH) with significant tumor contrast over normal muscle tissue (p < 0.005 at five weeks; p < 0.01 at four weeks). In addition, the TSPO-labeled TBHs demonstrated significant contrast over the TBHs of mice injected with free NIR dye (p < 0.001 at four and five weeks) as well as over the TSPO-labeled non-tumor-bearing hemispheres (NTBHs) of control mice (p < 0.005 at four and five weeks). Overall, TSPO-targeted molecular imaging appears useful for visualizing and quantifying breast cancer xenografts propagated in the murine brain and may assist in preclinical detection, diagnosis and monitoring of metastatic disease as well as drug discovery. Furthermore, these results indicate it should be possible to perform TSPO-imaging of breast cancer cells in the brain using radiolabeled TSPO-targeted agents, particularly in light of the fact that [11C]-labeled TSPO probes such as [11C]-PK 11195 have been successfully used to image gliomas in the clinic.

Citing Articles

Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease.

Li Y, Chen L, Li L, Sottas C, Petrillo S, Lazaris A iScience. 2021; 24(5):102457.

PMID: 34013171 PMC: 8113880. DOI: 10.1016/j.isci.2021.102457.


TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions.

Cohen A, Li J, Hight M, McKinley E, Fu A, Payne A Clin Cancer Res. 2020; 26(22):5914-5925.

PMID: 32933996 PMC: 7669725. DOI: 10.1158/1078-0432.CCR-20-1214.


A self-internalizing mitochondrial TSPO targeting imaging probe for fluorescence, MRI and EM.

Samuelson L, Anderson B, Bai M, Dukes M, Hunt C, Casey J RSC Adv. 2020; 4(18):9003-9011.

PMID: 32051760 PMC: 7015156. DOI: 10.1039/c3ra47161f.


Profiling of differentially expressed genes in adipose tissues of multiple symmetric lipomatosis.

Chen K, Wang L, Yang W, Wang C, Hu G, Mo Z Mol Med Rep. 2017; 16(5):6570-6579.

PMID: 28901441 PMC: 5865826. DOI: 10.3892/mmr.2017.7437.


Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model.

Tantawy M, Manning H, Peterson T, Colvin D, Gore J, Lu W Mol Imaging Biol. 2017; 20(2):200-204.

PMID: 28822038 PMC: 5903879. DOI: 10.1007/s11307-017-1113-7.


References
1.
Trehin R, Figueiredo J, Pittet M, Weissleder R, Josephson L, Mahmood U . Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia. 2006; 8(4):302-11. PMC: 1600680. DOI: 10.1593/neo.05751. View

2.
Peters T . Image-guidance for surgical procedures. Phys Med Biol. 2006; 51(14):R505-40. DOI: 10.1088/0031-9155/51/14/R01. View

3.
Maaser K, Grabowski P, Sutter A, Hopfner M, Foss H, Stein H . Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer. Clin Cancer Res. 2002; 8(10):3205-9. View

4.
Ichioka T, Miyatake S, Asai N, Kajimoto Y, Nakagawa T, Hayashi H . Enhanced detection of malignant glioma xenograft by fluorescein-human serum albumin conjugate. J Neurooncol. 2004; 67(1-2):47-52. DOI: 10.1023/b:neon.0000021783.62610.1b. View

5.
Wyatt S, Manning H, Bai M, Bailey S, Gallant P, Ma G . Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol. 2009; 12(3):349-58. PMC: 6544016. DOI: 10.1007/s11307-009-0270-8. View